Document is current
Any future updates will be listed below
-
Authors
Shinn, Maxwell https://orcid.org/0000-0002-7424-4230
Hu, Amber
Turner, Laurel
Noble, Stephanie https://orcid.org/0000-0002-4804-5553
Preller, Katrin H. https://orcid.org/0000-0003-0413-7672
Ji, Jie Lisa https://orcid.org/0000-0002-6280-9070
Moujaes, Flora
Achard, Sophie https://orcid.org/0000-0001-9448-1199
Scheinost, Dustin https://orcid.org/0000-0002-6301-1167
Constable, R. Todd https://orcid.org/0000-0001-5661-9521
Krystal, John H. https://orcid.org/0000-0001-6952-1726
Vollenweider, Franz X. https://orcid.org/0000-0001-9053-6164
Lee, Daeyeol
Anticevic, Alan
Bullmore, Edward T.
Murray, John D. https://orcid.org/0000-0003-4115-8181
-
Funding
Funding for this research was provided by:
European Molecular Biology Organization (ALTF 712-2021)
Winston Churchill Foundation of the United States
Gruber Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K00MH122372, R01MH112746)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2ZHP1\161626, 01EW1908)
Agence Nationale de la Recherche (ANR-20-NEUC-003-01, ANR-19-P3IA-0003)
Heffter Research Institute (1-190420)
Simons Foundation
DH | National Institute for Health Research (Senior Investigator award, Cambridge Biomedical Research Centre)
- License Information
-
More Information
Article History
Received: 27 April 2022
Accepted: 14 March 2023
First Online: 24 April 2023
Competing interests
: K.H.P. is currently an employee of Hoffmann-La Roche. J.H.K. has consulting agreements (less than $5,000 per year) with the following: Aptinyx; Atai Life Sciences; AstraZeneca Pharmaceuticals; Biogen; Biomedisyn Corporation; Bionomics; Boehringer Ingelheim; Cadent Therapeutics; Clexio Bioscience; COMPASS Pathways; Concert Pharmaceuticals; Epiodyne; EpiVario; Greenwich Biosciences; Heptares Therapeutics; Janssen Research & Development; Jazz Pharmaceuticals; Otsuka America Pharmaceutical; Perception Neuroscience Holdings; Spring Care; Sunovion Pharmaceuticals; Takeda Industries; and Taisho Pharmaceutical Company. J.H.K. serves on the scientific advisory boards of Biohaven Pharmaceuticals; BioXcel Therapeutics (Clinical Advisory Board); Cadent Therapeutics (Clinical Advisory Board); Cerevel Therapeutics; EpiVario; Eisai; Jazz Pharmaceuticals; Lohocla Research Corporation; Novartis Pharmaceuticals Corporation; PsychoGenics; Neumora Therapeutics; Tempero Bio; and Terran Biosciences. J.H.K. is on the board of directors of Freedom Biosciences. J.H.K. has stock and/or stock options in Biohaven Pharmaceuticals; Sage Pharmaceuticals; Spring Care; Biohaven Pharmaceuticals Medical Sciences; EpiVario; Neumora Therapeutics; Terran Biosciences; and Tempero Bio. J.H.K. is editor of <i>Biological Psychiatry</i> with income greater than $10,000. D.L. is a co-founder of Neurogazer. A.A. and J.D.M. are co-founders of Manifest Technologies and serve on the technical advisory board of Neumora Therapeutics. E.T.B. serves on the scientific advisory board of Sosei Heptares and as a consultant for GlaxoSmithKline. The remaining authors declare no competing interests.
